Denise Fabian

Dr. Denise Fabian


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2024 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
ZCZeta Chow
Zeta Chow
DFDenise Fabian
Denise Fabian

6 October 2025 in Gynecologic Oncology
Verified
Journal Article
Open access
DCDana M. Chase
Dana M. Chase
HHHelen Q. Huang
Helen Q. Huang
WDWei Deng
Wei Deng
WKWui-Jin Koh
Wui-Jin Koh
WRWilliam H Rodgers
William H Rodgers
SRSang Young Ryu
Sang Young Ryu
To prospectively evaluate the impact of adjuvant chemoradiation (RT + CIS) versus radiation (RT) on quality of life (QOL) and patient-reported outcomes (PROs) among patients with intermediate-risk, stage I-IIA cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy. Patients enrolled in GOG-0263 completed PRO/QOL assessments at baseline, 3, 7, and 36 weeks using the FACT-Cx Trial Outcome Index (FACT-Cx TOI), FACT/GOG-Neurotoxicity subscale (FACT/GOG-Ntx-4), the worst pain item from the Brief Pain Inventory (BPI), and five gastrointestinal/genitourinary (GI/GU) symptom items. Linear mixed models adjusted for baseline score, treatment, age, performance status, and country. Among 316 randomized eligible patients (RT + CIS: n = 158; RT: n = 158), questionnaire completion rates were 98 %, 90 %, 88 %, and 81 % at baseline, weeks 3, 7, and 36, respectively. Patients receiving RT + CIS reported a mean FACT-Cx TOI score 5.1 points lower than RT at 3 weeks (97.5 % CI: -8.6 to -1.6; p = 0.004) and 6.3 points lower at 7 weeks (97.5 % CI: -10.2 to -2.4; p = 0.002). By 36 weeks, scores had returned to baseline in both groups, with no significant difference (p = 0.386). Patient-reported neuropathy scores (FACT/GOG-Ntx-4) did not differ significantly between groups at any time point (p = 0.82). Patient-reported GI/GU symptoms and pain worsened at 3 weeks in both arms, followed by recovery to baseline by 36 weeks. QOL declined in both groups after treatment initiation, with greater short-term deterioration in the RT + CIS group. By 36 weeks, QOL and other PROs returned to baseline in both groups. Neuropathy, GI/GU symptoms, and pain showed no significant differences between treatment arms over time.

1 June 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DFDenise Fabian
Denise Fabian
MLMorgan S. Levy
Morgan S. Levy
DPDava W. Piecoro
Dava W. Piecoro
DNDana Napier
Dana Napier
RMRachel W. Miller
Rachel W. Miller
CKCharles A. Kunos
Charles A. Kunos
Introduction: [ 212 Pb]Pb-PSV-359 is a radiopharmaceutical utilizing an alpha particle-emitting radionuclide lead-212 ( 212 Pb) and a fibroblast activation protein (FAPα)-targeted antagonist being assessed as anticancer treatment. Prior nuclear imaging studies have shown that almost all cancer-associated fibroblasts within uterine cervix cancer tumors express the radiopharmaceutical target FAP when assessed by radiotracer uptake criteria. It is unknown whether immunohistopathology supports this claim. Therapeutic response to [ 212 Pb]Pb-PSV-359 likely associates with FAP expression, and thus, it seems sensible to evaluate FAP immunoreactivity as a triage biomarker when intending to use this agent against persistent, recurrent or metastatic uterine cervix cancer. Methods: We examined a series of 37 uterine cervix cancer paraffin-embedded tumors to determine whether this tumor type expresses FAP at a sufficient cell proportion and staining intensity for an immunoreactive score (IRS) of six or higher, as [ 212 Pb]Pb-PSV-359 is currently being evaluated in clinical trials only against tumors demonstrating radiotracer uptake criteria rather than also by immunoreactivity criteria. Results: The results show that 28 of 34 (82%) uterine cervix cancer tumors with evaluable desmoplastic stroma had cancer-associated fibroblasts expressing FAP. Twenty (59%) tumors scored at an IRS six or higher. Primary tumors from patients with stage IVB disease at diagnosis (n=11) or metastatic tumors (n=6) had cancer-associated fibroblasts expressing FAP most often (76%). Discussion: Cancer-associated fibroblast FAP immunoreactivity in this series indicates that [ 212 Pb]Pb-PSV-359 radiopharmaceutical therapy might have usefulness in women with persistent, recurrent or metastatic uterine cervix cancer. A phase I clinical trial inclusive of metastatic uterine cervix cancer patients is underway (NCT06710756).

5 October 2023 in Cancers
Verified
Journal Article
Open access
PDF file
BWBrien Washington
Brien Washington
DCDennis Cheek
Dennis Cheek
DFDenise Fabian
Denise Fabian
MKMahesh Kudrimoti
Mahesh Kudrimoti
DPDamodar Pokhrel
Damodar Pokhrel
WLWei Luo
Wei Luo
Meeting dose prescription is critical to control tumors in radiation therapy. Interfraction dose variations (IDVs) from the prescribed dose in high dose rate brachytherapy (HDR) would cause the target dose to deviate from the prescription but their clinical effect has not been widely discussed in the literature. Our previous study found that IDVs followed a left-skewed distribution. The clinical effect of the IDVs in 100 cervical cancer HDR patients will be addressed in this paper. An in-house Monte Carlo (MC) program was used to simulate clinical outcomes by convolving published tumor dose response curves with IDV distributions. The optimal dose and probability of risk-free local control (RFLC) were calculated using the utility model. The IDVs were well-fitted by the left-skewed Beta distribution, which caused a 3.99% decrease in local control probability and a 1.80% increase in treatment failure. Utility with respect to IDV uncertainty increased the RFLC probability by 6.70% and predicted an optimal dose range of 83 Gy–91 Gy EQD2. It was also found that a 10 Gy dose escalation would not affect toxicity. In conclusion, HRCTV IDV uncertainty reduced LC probabilities and increased treatment failure rates. A dose escalation may help mitigate such effects.

14 January 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
DFDenise Fabian
Denise Fabian
MBMolly E. Buffington
Molly E. Buffington
BCBrianna S. Cagle
Brianna S. Cagle
SKSteve M. Keefe
Steve M. Keefe
MSMichael K. Schultz
Michael K. Schultz
CKCharles A. Kunos
Charles A. Kunos
Designing and interpreting early phase trials of theranostic radiopharmaceuticals remains challenging because it is difficult to isolate effective levels of activity in enriched patient populations that would be worth following up in later-phase development. This study explores the known challenges and emerging opportunities for clinical research on patients with uterine cervical cancer. We identified eight randomized combination trials for advanced-stage uterine cervix cancer that were activated between 2011 and 2022 and tabulated their results to determine whether combinations were better than individual constituents and which suitable study population is best situated for the study of a new theranostic agent. In this overview, we discuss exploitable vulnerabilities and radiobiology of cancer-associated fibroblasts, as these stromal cells are targets for nuclear and therapeutic radiation medicine. We also discuss investigational drugs that hold promise for the theranostic treatment of persistent, recurrent, or metastatic uterine cervical cancer, including inhibitors of fibroblast activation protein-alpha and ribonucleotide reductase. In our expert opinion, the development of a theranostic radiopharmaceutical should pursue the eventual goal of being tested in a randomized phase II monotherapy setting.

28 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
CKCharles Kunos
Charles Kunos
RMRachel W. Miller
Rachel W. Miller
DFDenise Fabian
Denise Fabian
Background: Prior preclinical studies showed promising antitumor activity and an acceptable safety profile associated with radiopharmaceuticals for patients with metastatic, persistent, or recurrent uterine cervix cancers. Whether the addition of a radiopharmaceutical to chemotherapy would significantly increase progression-free survival in such patients is untested. Our retrospective study sought to associate the line of treatment and progression-free survival as benchmarks for next-generation radiopharmaceutical development. Methods: We grouped metastatic, persistent, or recurrent uterine cervix cancer patients not amenable to curable surgery or radiotherapy between 2002 and 2023 by the line of doublet, triplet, and quadruplet chemotherapy or another intervention. After the first-line treatment, patients were monitored for radiographic progression every three months for up to three years. The primary endpoints were the first and any second or third progression-free survival intervals. Results: A total of 127 patients contributed demographic, tumor, line of treatment, and outcome data with a median follow-up of 18 months (25–75% interquartile range: 9 to 37 months). After the first-line treatment, 113 patients had local or distant progression or died from any cause, most often death from the disease (67%). Median progression-free survivals were 5.5 months (95% confidence interval: 4.8–6.0 months), 5.3 months (95% confidence interval: 4.5–6.3 months), and 3.0 months (95% confidence interval: 2.1–3.7 months) for the first-, second-, and third-line treatments, respectively. For a first-line cisplatin-containing regimen, the median progression-free survival was 6.5 months (95% confidence interval: 5.5–7.7 months). Conclusions: This study highlights the limited efficacy of current treatments for metastatic, persistent, or recurrent uterine cancer patients. A five-month progression-free survival might serve as a benchmark for the development of novel therapies in clinical efficacy trials, such as radiopharmaceuticals.